BTIG raised the firm’s price target on Denali Therapeutics (DNLI) to $36 from $32 and keeps a Buy rating on the shares. The company has established a clear path to get complex drugs approved and can now leverage their expertise and the quality FDA relationship they have built to fast-track the pipeline, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics price target lowered to $34 from $37 at Stifel
- Denali Therapeutics: Underappreciated Hunter Syndrome Launch and 2026 CNS Pipeline Catalysts Support Buy Rating
- Denali Therapeutics reports Q4 EPS (73c), consensus (75c)
- Denali Therapeutics initiated with a Peer Perform at Wolfe Research
- Denali Therapeutics: Differentiated Hunter Syndrome Strategy and Non-Viral Platform Support Buy Rating and Long-Term Franchise Upside